KUALA LUMPUR, Sept 17 -- The National Medical Products Administration (NMPA) has approved the oral formulation of Akynzeo® to treat chemotherapy-induced nausea and vomiting (CINV) in China.
This follows the announcement made by Helsinn Healthcare S.A., a Swiss-based pharmaceutical group and market leader in pain management, namely Mundipharma China Pharmaceutical.
Under the terms of agreement, Helsinn will be responsible for supplying the drug to Mundipharma and co-detailing the product in Shanghai while retaining all international development rights, including clinical development activities.
Meanwhile, the Mundipharma China Pharmaceutical has exclusive marketing, promotion and sale rights for the oral formulation of Akynzeo® in China.
Helsinn Group vice-chairman and chief executive officer, Riccardo Braglia said: “Lack of control of CINV is a problem despite the availability of several antiemetics. We are pleased that Akynzeo® that targets two CINV critical pathways in a single dose will help patients and their families, also in China.
“We are also very pleased to be working in partnership with Mundipharma Pharmaceutical. Their expert knowledge and network in China will be invaluable as we begin to market Akynzeo® in this strategically important region.”